Loading...
•
Mar 31, 2020
Ocular Therapeutix Q1 2020 Earnings Report
Ocular Therapeutix reported financial results for the first quarter ended March 31, 2020, featuring a 31% sequential increase in DEXTENZA net product revenue compared to the previous quarter and announced positive Phase 3 clinical trial results for DEXTENZA in allergic conjunctivitis.
Key Takeaways
Ocular Therapeutix announced its Q1 2020 financial results, highlighting a 31% sequential increase in DEXTENZA net product revenue, reaching $2.1 million. The company also reported positive Phase 3 clinical trial results for DEXTENZA in allergic conjunctivitis and plans to file an sNDA with the FDA by the end of 2020.
DEXTENZA net product revenue increased by 31% sequentially compared to Q4 2019, reaching $2.1 million.
Positive Phase 3 clinical trial results were announced for DEXTENZA in treating allergic conjunctivitis.
The company plans to file an sNDA with the FDA for DEXTENZA by the end of 2020.
Clinical programs are progressing, potentially setting new standards of care in areas like wet AMD, glaucoma, dry eye, and post-operative pain and inflammation.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
Ocular Therapeutix is progressing with its clinical programs and anticipates regulatory and competitive landscape changes to positively impact its future prospects.
Positive Outlook
- Continued development programs performing well in the clinic.
- Changes in the regulatory and competitive landscapes provide increased confidence in the future.
- Clinical program successes are tracking toward target product profiles.
- External environment changes make the company more confident in regulatory pathways and potential market acceptability.
- Increased interest in hands-free products like DEXTENZA due to COVID-19 pandemic concerns over infection risk.